IMMUNOVANT INC. 2023-2024 Proxy Voting Records

Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2024 Annual Meeting of Stockholders and until the successors are duly elected and qualified: Nominees: Douglas Hughes

IMMUNOVANT INC.’s own tally for this item (“Elect Director: Douglas Hughes”): 96,590,902 for, 19,639,908 withheld, per its Form 8-K filed August 23, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors Peter Salzmann, M.D., M.B.A., Douglas Hughes and George Migausky were each elected to serve as a member of Immunovant's Board of Directors, or the Board, until the 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until …”
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 6,093,893 for, 10,089,147 withheld, 593,838 abstained.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2024 Annual Meeting of Stockholders and until the successors are duly elected and qualified: Nominees: George Migausky

IMMUNOVANT INC.’s own tally for this item (“Elect Director: George Migausky”): 96,550,901 for, 19,679,909 withheld, per its Form 8-K filed August 23, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors Peter Salzmann, M.D., M.B.A., Douglas Hughes and George Migausky were each elected to serve as a member of Immunovant's Board of Directors, or the Board, until the 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until …”
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 6,096,369 for, 10,086,671 withheld, 593,838 abstained.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2024 Annual Meeting of Stockholders and until the successors are duly elected and qualified: Nominees: Peter Salzmann, M.D., M.B.A.

IMMUNOVANT INC.’s own tally for this item (“Elect Director: Peter Salzmann, M.D., M.B.A.”): 98,532,525 for, 17,698,285 withheld, per its Form 8-K filed August 23, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 5,533,184 for, 10,668,823 withheld, 574,871 abstained.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of our named executive officers.

IMMUNOVANT INC.’s own tally for this item (“3. Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers”): 115,397,185 for, 825,452 against — passed, per its Form 8-K filed August 23, 2023 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3- Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers The stockholders approved, on a non-binding advisory basis, the compensation of Immunovant's named executive officers, as disclosed in the Proxy Statement, including the compensation …”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 49 managers: 16,208,411 for, 568,467 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 121 managers: 32,949,798 for, 749,115 against, 8,900 abstained. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending March 31,2024.

IMMUNOVANT INC.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 121,206,460 for, 5,261 against — passed, per its Form 8-K filed August 23, 2023 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as Immunovant's independent registered public accounting firm for the year ending March 31, 2024, by the follo…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 16,776,878 for.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.